PROGNOSTIC FACTORS FOR THE OUTCOME OF METHOTREXATE TREATMENT IN RHEUMATOID-ARTHRITIS

被引：0
作者：
KOLARZ, G
MAYRHOFER, F
PEICHL, P
POSCH, E
SCHERAK, O
SINGER, F
THUMB, N
WOTTAWA, A
机构：
[1] Institute for Rheumatology, Baden, A-2500
[2] 2nd Med. Dept, Kaiser Franz Josef-Spital, Wien, A-1100
来源：
CLINICAL RHEUMATOLOGY | 1995年 / 14卷 / 05期
关键词：
METHOTREXATE IN RA; OUTCOME OF METHOTREXATE TREATMENT;
D O I：
10.1007/BF02208147
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Aim of the study: To evaluate various symptoms/findings for their ability as prognostic markers in MTX-therapy in patients with rheumatoid arthritis. Patients and methods: 48 patients with definite RA were treated with MTX in a dose of 7,5 to 10 mg weekly for one year. Before MTX-therapy, six and twelve months after initiation of treatment the following examinations were recorded: duration of morning stiffness, grip strength, functional class according to Steinbrocker, Ritchie's Index, ESR, blood count, C-reactive protein, rheumatoid factor, antinuclear antibodies, electrophoresis, ALAT,ASAT, LDH, gamma-GT, alkaline phosphatase, uric acid, BUN, serum creatinine and urine analysis. In 29 patients additionnally IL-1 alpha, IL-1 beta, IL-2, sIL-2-R, IL-6, IL-8, IL-8AB and sCD-8 were determined at the start and after twelve months of treatment. Statistical analysis was performed by means of a standard SAS programme. Results: After one year 62,5% of the patients showed good or moderate improvement of the disease. In 11 patients minor side effects were observed, in 6 patients (12,5%) treatmet had to be terminated because of side effects. Good results with MTX were independent of duration of disease, sex, age, grip strength,joint score and seropositivity, but depended significantly on the functional capacity: patients with minor handicap had the greatest benefit from the treatment. Independent of the functional capacity patients with high levels of IL-1 beta and low levels of IL-8 antibodies both showed favourable results as well. Conclusion: The prediction of the outcome of a treatment with a disease modifying anti rheumatic drug in a single patient is highly desirable. For MTX it could well be worth studying IL-1 beta and IL-8-antibody levels in a larger group of patients before initiation of MTX therapy to confirm these preliminary results.
引用
收藏
页码：515 / 518
页数：4
相关论文
共 12 条
  • [1] Arnett F.C., Edworthy S.M., Bloch D.A., McShane D.J., Fries J.F., Medsger T.A., Mitchell D.M., Neustadt D.H., Pinals R.S., Schaller J.-G., Sharp J.T., Wilder R.L., Hunder G.G., The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis, Arthritis Rheum, 31, pp. 315-324, (1988)
  • [2] Arnold M.H., O'Callaghan J., McCredie M., Beller E.M., Kelly D.E., Brooks P.M., Comparative controlled trial of low-dose weekly methotrexate versus azathioprine in rheumatoid arthritis: 3-year prospective study, Br J Rheumatol, 29, pp. 120-125, (1990)
  • [3] Barrera P., Boerboo A.M.T., Janssen E.M., Sauerwein R.W., Gallati H., Mulder J., de Boo T., Demacker P.N.M., van de Putte L.B.A., van der Meer J.W.M., Circulating soluble tumor necrosis factor receptors, interleukin-2-receptors, tumor necrosis factor α, and interleukin-6 levels in rheumatoid arthritis: longitudinal evaluation during methotrexate and azathioprine therapy, Arthritis Rheum, 36, pp. 1070-1079, (1993)
  • [4] Crilly A., Madhok R., The effects of methotrexate on soluble interleukin-2 receptor levels in rheumatoid arthritis: comment on the article by Barrera et al, Arthritis Rheum, 37, pp. 597-598, (1994)
  • [5] Furst D.E., Kremer J.M., Methotrexate in rheumatoid arthritis, Arthritis Rheum, 31, pp. 305-314, (1988)
  • [6] Hanrahan P.S., Scrivens G.A., Russel A.S., Prospective long-term follow-up of methotrexate therapy in rheumatoid arthritis: toxicity, efficacy and radiological progression, Br J Rheumatol, 28, pp. 147-153, (1989)
  • [7] Peichl P., Ceska M., Effenberger F., Haberhauer G., Broell H., Lindley I.J.D., Presence of NAP-1/IL-8 in synovial fluids indicates a possible pathogenic role in rheumatoid arthritis, Scand J Immunol, 34, pp. 333-339, (1991)
  • [8] Peichl P., Ceska M., Broell H., Effenberger F., Lindley I.J.D., Human neutrophil activating peptide/interleukin-8 acts as an autoantigen in rheumatoid arthritis, Ann Rheum Dis, 51, pp. 19-22, (1992)
  • [9] Polisson R.P., Dooley M.A., Dawson D.V., Pisetsky D.S., Interleukin-2 receptor levels in the sera of rheumatoid arthritis patients treated with methotrexate, Arthritis Rheum, 37, (1994)
  • [10] Rau R., Methotrexat-Behandlung der chronischen Polyarthritis, Dtsch med Wschr, 112, pp. 1142-1147, (1987)
12